Global Acute Myeloid Leukemia Therapeutics

Acute Myeloid Leukemia Therapeutics Comprehensive Study by Type (Pipeline Drugs, Chemotherapy Drugs, Chemotherapy Regimens), Application (Hospitals, Clinics, Home Care), Drug Type (Bosutinib, Vidaza, Omapro, Quizartinib, Dacogen, Clolar, Gleevac, Sprycel, Others), Disease Type (Undifferentiated Acute Myeloblastic, Acute Myeloblastic Leukemia with Minimal Maturation, Acute Myeloblastic Leukemia with Maturation, Acute Promyelocytic Leukemia (APL), Acute Myelomonocytic Leukemia, Acute Myelomonocytic Leukemia with Eosinophilia, Acute Monocytic Leukemia, Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia) Players and Region - Global Market Outlook to 2028

Acute Myeloid Leukemia Therapeutics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Acute Myeloid Leukemia Therapeutics Market Scope
Acute myeloid leukemia is the second most common type (after acute lymphoblastic leukemia) of leukemia diagnosed in infants. Approximately 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely related to age. About 90% of acute myeloid leukemia are diagnosed in middle age. The incidence rate of acute myeloid leukemia is high in men and women over 50 years of age. The Acute Myeloid Leukemia Market is divided into two types namely, acute myeloid leukemia in childhood and acute myeloid leukemia in adults. Acute myeloid leukemia (AML) is a type of blood cancer that usually affects white blood cells (WBC). However, it can also occur in other types of blood-forming cells. AML is the rapid production of abnormal WBCs that accumulate in the bone marrow and affect the production of normal blood cells. AML: Acute myeloid leukemia is a serious disease and the most common leukemia in adults. According to a report by the American Cancer Society, the median age at first diagnosing AML is 64 years. With a few days without treatment, AML develops rapidly, and within a few weeks, the patient becomes seriously ill. Because of its rapid onset and harshness in nature, there is no staging system for acute myeloid leukemia (AML). The treatment of acute myeloid leukemia (AML) has changed over the past 4 decades. The drug approval process is difficult for AML (many drugs have not been approved by the USFDA, such as Laromustine, Dacogen, and Tipitarnib). Efforts have been made to introduce new therapies to the AML market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAmbit Biosciences Corporation (United States), Celgene Corporation (United States), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), GlaxoSmithKline (United Kingdom), Cephalon Inc. (United States), Clavis Pharma ASA (United States), Eisai Co. Ltd. (Japan), Genzyme Corporation (United States), Sunesis Pharmaceuticals Inc. (United States) and Abbvie Inc. (United States)
CAGR%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Acute Myeloid Leukemia Therapeutics market throughout the predicted period.

Ambit Biosciences Corporation (United States), Celgene Corporation (United States), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), GlaxoSmithKline (United Kingdom), Cephalon Inc. (United States), Clavis Pharma ASA (United States), Eisai Co. Ltd. (Japan), Genzyme Corporation (United States), Sunesis Pharmaceuticals Inc. (United States) and Abbvie Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Astellas Pharma Inc. (Japan) and CTI Biopharma Corp (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Acute Myeloid Leukemia Therapeutics market by Type , by Application (Hospitals, Clinics and Home Care) and Region with country level break-up.

On the basis of geography, the market of Acute Myeloid Leukemia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2022.

Market Leaders and their expansionary development strategies
In 2021, Novartis International AG acquired Cadent Therapeutics, a biotechnology business in the clinical stages that creates medications for neurological and mental illnesses. Expanding Novartis' range of cancer and gene therapy medications, especially AML therapeutics, was the goal of the acquisition.
In 2020, a very effective COVID-19 vaccine was created in collaboration between Pfizer Inc. and the German biotech business BioNTech SE. The businesses created BNT162b2, a potential therapy for AML, using the same technique. Clinical trials for the medicine are presently underway, and the findings are encouraging.
In, August 2017 the U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation. The use of Idhifa was associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.

Influencing Trend:
Increasing Level of Carcinogens in the Environment and The Availability of the Treatment and Launch of Newer Drugs

Market Growth Drivers:
Rise in Awareness about the Leukemia Treatment, Increasing Number of Cancer Hospitals, Growing Population of Acute Myeloid Leukemia and A Rise in Changing Lifestyle and Family History

Challenges:
Lack of Standardized Treatment

Restraints:
Increasing Number of Stem Cell Transplant

Opportunities:
Increasing Inclination towards Therapies Such As Targeted Therapies Resulting In Low Collateral Damage and Stronger Efficacy, Rise in Advanced Healthcare Infrastructure and Need for Targeted Therapies and An Upsurge in Huge Investment for the Development of Pipeline Drugs

Key Target Audience
Providers of Acute Myeloid Leukemia Therapeutics, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users

Report Objectives / Segmentation Covered

By Type
  • Pipeline Drugs
  • Chemotherapy Drugs
  • Chemotherapy Regimens
By Application
  • Hospitals
  • Clinics
  • Home Care
By Drug Type
  • Bosutinib
  • Vidaza
  • Omapro
  • Quizartinib
  • Dacogen
  • Clolar
  • Gleevac
  • Sprycel
  • Others

By Disease Type
  • Undifferentiated Acute Myeloblastic
  • Acute Myeloblastic Leukemia with Minimal Maturation
  • Acute Myeloblastic Leukemia with Maturation
  • Acute Promyelocytic Leukemia (APL)
  • Acute Myelomonocytic Leukemia
  • Acute Myelomonocytic Leukemia with Eosinophilia
  • Acute Monocytic Leukemia
  • Acute Erythroid Leukemia
  • Acute Megakaryoblastic Leukemia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Awareness about the Leukemia Treatment
      • 3.2.2. Increasing Number of Cancer Hospitals
      • 3.2.3. Growing Population of Acute Myeloid Leukemia
      • 3.2.4. A Rise in Changing Lifestyle and Family History
    • 3.3. Market Challenges
      • 3.3.1. Lack of Standardized Treatment
    • 3.4. Market Trends
      • 3.4.1. Increasing Level of Carcinogens in the Environment
      • 3.4.2. The Availability of the Treatment and Launch of Newer Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acute Myeloid Leukemia Therapeutics, by Type, Application, Drug Type, Disease Type and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Acute Myeloid Leukemia Therapeutics (Value)
      • 5.2.1. Global Acute Myeloid Leukemia Therapeutics by: Type (Value)
        • 5.2.1.1. Pipeline Drugs
        • 5.2.1.2. Chemotherapy Drugs
        • 5.2.1.3. Chemotherapy Regimens
      • 5.2.2. Global Acute Myeloid Leukemia Therapeutics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Home Care
      • 5.2.3. Global Acute Myeloid Leukemia Therapeutics by: Drug Type (Value)
        • 5.2.3.1. Bosutinib
        • 5.2.3.2. Vidaza
        • 5.2.3.3. Omapro
        • 5.2.3.4. Quizartinib
        • 5.2.3.5. Dacogen
        • 5.2.3.6. Clolar
        • 5.2.3.7. Gleevac
        • 5.2.3.8. Sprycel
        • 5.2.3.9. Others
      • 5.2.4. Global Acute Myeloid Leukemia Therapeutics by: Disease Type (Value)
        • 5.2.4.1. Undifferentiated Acute Myeloblastic
        • 5.2.4.2. Acute Myeloblastic Leukemia with Minimal Maturation
        • 5.2.4.3. Acute Myeloblastic Leukemia with Maturation
        • 5.2.4.4. Acute Promyelocytic Leukemia (APL)
        • 5.2.4.5. Acute Myelomonocytic Leukemia
        • 5.2.4.6. Acute Myelomonocytic Leukemia with Eosinophilia
        • 5.2.4.7. Acute Monocytic Leukemia
        • 5.2.4.8. Acute Erythroid Leukemia
        • 5.2.4.9. Acute Megakaryoblastic Leukemia
      • 5.2.5. Global Acute Myeloid Leukemia Therapeutics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Acute Myeloid Leukemia Therapeutics (Price)
      • 5.3.1. Global Acute Myeloid Leukemia Therapeutics by: Type (Price)
  • 6. Acute Myeloid Leukemia Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ambit Biosciences Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bristol-Myers Squibb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis International AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cephalon Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Clavis Pharma ASA (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eisai Co. Ltd. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Genzyme Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sunesis Pharmaceuticals Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Abbvie Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Acute Myeloid Leukemia Therapeutics Sale, by Type, Application, Drug Type, Disease Type and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Acute Myeloid Leukemia Therapeutics (Value)
      • 7.2.1. Global Acute Myeloid Leukemia Therapeutics by: Type (Value)
        • 7.2.1.1. Pipeline Drugs
        • 7.2.1.2. Chemotherapy Drugs
        • 7.2.1.3. Chemotherapy Regimens
      • 7.2.2. Global Acute Myeloid Leukemia Therapeutics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Home Care
      • 7.2.3. Global Acute Myeloid Leukemia Therapeutics by: Drug Type (Value)
        • 7.2.3.1. Bosutinib
        • 7.2.3.2. Vidaza
        • 7.2.3.3. Omapro
        • 7.2.3.4. Quizartinib
        • 7.2.3.5. Dacogen
        • 7.2.3.6. Clolar
        • 7.2.3.7. Gleevac
        • 7.2.3.8. Sprycel
        • 7.2.3.9. Others
      • 7.2.4. Global Acute Myeloid Leukemia Therapeutics by: Disease Type (Value)
        • 7.2.4.1. Undifferentiated Acute Myeloblastic
        • 7.2.4.2. Acute Myeloblastic Leukemia with Minimal Maturation
        • 7.2.4.3. Acute Myeloblastic Leukemia with Maturation
        • 7.2.4.4. Acute Promyelocytic Leukemia (APL)
        • 7.2.4.5. Acute Myelomonocytic Leukemia
        • 7.2.4.6. Acute Myelomonocytic Leukemia with Eosinophilia
        • 7.2.4.7. Acute Monocytic Leukemia
        • 7.2.4.8. Acute Erythroid Leukemia
        • 7.2.4.9. Acute Megakaryoblastic Leukemia
      • 7.2.5. Global Acute Myeloid Leukemia Therapeutics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Acute Myeloid Leukemia Therapeutics (Price)
      • 7.3.1. Global Acute Myeloid Leukemia Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acute Myeloid Leukemia Therapeutics: by Type(USD Million)
  • Table 2. Acute Myeloid Leukemia Therapeutics Pipeline Drugs , by Region USD Million (2017-2022)
  • Table 3. Acute Myeloid Leukemia Therapeutics Chemotherapy Drugs , by Region USD Million (2017-2022)
  • Table 4. Acute Myeloid Leukemia Therapeutics Chemotherapy Regimens , by Region USD Million (2017-2022)
  • Table 5. Acute Myeloid Leukemia Therapeutics: by Application(USD Million)
  • Table 6. Acute Myeloid Leukemia Therapeutics Hospitals , by Region USD Million (2017-2022)
  • Table 7. Acute Myeloid Leukemia Therapeutics Clinics , by Region USD Million (2017-2022)
  • Table 8. Acute Myeloid Leukemia Therapeutics Home Care , by Region USD Million (2017-2022)
  • Table 9. Acute Myeloid Leukemia Therapeutics: by Drug Type(USD Million)
  • Table 10. Acute Myeloid Leukemia Therapeutics Bosutinib , by Region USD Million (2017-2022)
  • Table 11. Acute Myeloid Leukemia Therapeutics Vidaza , by Region USD Million (2017-2022)
  • Table 12. Acute Myeloid Leukemia Therapeutics Omapro , by Region USD Million (2017-2022)
  • Table 13. Acute Myeloid Leukemia Therapeutics Quizartinib , by Region USD Million (2017-2022)
  • Table 14. Acute Myeloid Leukemia Therapeutics Dacogen , by Region USD Million (2017-2022)
  • Table 15. Acute Myeloid Leukemia Therapeutics Clolar , by Region USD Million (2017-2022)
  • Table 16. Acute Myeloid Leukemia Therapeutics Gleevac , by Region USD Million (2017-2022)
  • Table 17. Acute Myeloid Leukemia Therapeutics Sprycel , by Region USD Million (2017-2022)
  • Table 18. Acute Myeloid Leukemia Therapeutics Others , by Region USD Million (2017-2022)
  • Table 19. Acute Myeloid Leukemia Therapeutics: by Disease Type(USD Million)
  • Table 20. Acute Myeloid Leukemia Therapeutics Undifferentiated Acute Myeloblastic , by Region USD Million (2017-2022)
  • Table 21. Acute Myeloid Leukemia Therapeutics Acute Myeloblastic Leukemia with Minimal Maturation , by Region USD Million (2017-2022)
  • Table 22. Acute Myeloid Leukemia Therapeutics Acute Myeloblastic Leukemia with Maturation , by Region USD Million (2017-2022)
  • Table 23. Acute Myeloid Leukemia Therapeutics Acute Promyelocytic Leukemia (APL) , by Region USD Million (2017-2022)
  • Table 24. Acute Myeloid Leukemia Therapeutics Acute Myelomonocytic Leukemia , by Region USD Million (2017-2022)
  • Table 25. Acute Myeloid Leukemia Therapeutics Acute Myelomonocytic Leukemia with Eosinophilia , by Region USD Million (2017-2022)
  • Table 26. Acute Myeloid Leukemia Therapeutics Acute Monocytic Leukemia , by Region USD Million (2017-2022)
  • Table 27. Acute Myeloid Leukemia Therapeutics Acute Erythroid Leukemia , by Region USD Million (2017-2022)
  • Table 28. Acute Myeloid Leukemia Therapeutics Acute Megakaryoblastic Leukemia , by Region USD Million (2017-2022)
  • Table 29. South America Acute Myeloid Leukemia Therapeutics, by Country USD Million (2017-2022)
  • Table 30. South America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 31. South America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 32. South America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 33. South America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 34. Brazil Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 35. Brazil Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 36. Brazil Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 37. Brazil Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 38. Argentina Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 39. Argentina Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 40. Argentina Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 41. Argentina Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 42. Rest of South America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 43. Rest of South America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 44. Rest of South America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 45. Rest of South America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 46. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Country USD Million (2017-2022)
  • Table 47. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 48. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 49. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 50. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 51. China Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 52. China Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 53. China Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 54. China Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 55. Japan Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 56. Japan Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 57. Japan Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 58. Japan Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 59. India Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 60. India Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 61. India Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 62. India Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 63. South Korea Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 64. South Korea Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 65. South Korea Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 66. South Korea Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 67. Taiwan Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 68. Taiwan Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 69. Taiwan Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 70. Taiwan Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 71. Australia Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 72. Australia Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 73. Australia Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 74. Australia Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 75. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 76. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 77. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 78. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 79. Europe Acute Myeloid Leukemia Therapeutics, by Country USD Million (2017-2022)
  • Table 80. Europe Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 81. Europe Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 82. Europe Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 83. Europe Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 84. Germany Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 85. Germany Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 86. Germany Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 87. Germany Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 88. France Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 89. France Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 90. France Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 91. France Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 92. Italy Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 93. Italy Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 94. Italy Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 95. Italy Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 96. United Kingdom Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 97. United Kingdom Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 98. United Kingdom Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 99. United Kingdom Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 100. Netherlands Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 101. Netherlands Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 102. Netherlands Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 103. Netherlands Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 104. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 105. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 106. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 107. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 108. MEA Acute Myeloid Leukemia Therapeutics, by Country USD Million (2017-2022)
  • Table 109. MEA Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 110. MEA Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 111. MEA Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 112. MEA Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 113. Middle East Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 114. Middle East Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 115. Middle East Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 116. Middle East Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 117. Africa Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 118. Africa Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 119. Africa Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 120. Africa Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 121. North America Acute Myeloid Leukemia Therapeutics, by Country USD Million (2017-2022)
  • Table 122. North America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 123. North America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 124. North America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 125. North America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 126. United States Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 127. United States Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 128. United States Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 129. United States Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 130. Canada Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 131. Canada Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 132. Canada Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 133. Canada Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 134. Mexico Acute Myeloid Leukemia Therapeutics, by Type USD Million (2017-2022)
  • Table 135. Mexico Acute Myeloid Leukemia Therapeutics, by Application USD Million (2017-2022)
  • Table 136. Mexico Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2017-2022)
  • Table 137. Mexico Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2017-2022)
  • Table 138. Acute Myeloid Leukemia Therapeutics: by Type(USD/Units)
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Acute Myeloid Leukemia Therapeutics: by Type(USD Million)
  • Table 151. Acute Myeloid Leukemia Therapeutics Pipeline Drugs , by Region USD Million (2023-2028)
  • Table 152. Acute Myeloid Leukemia Therapeutics Chemotherapy Drugs , by Region USD Million (2023-2028)
  • Table 153. Acute Myeloid Leukemia Therapeutics Chemotherapy Regimens , by Region USD Million (2023-2028)
  • Table 154. Acute Myeloid Leukemia Therapeutics: by Application(USD Million)
  • Table 155. Acute Myeloid Leukemia Therapeutics Hospitals , by Region USD Million (2023-2028)
  • Table 156. Acute Myeloid Leukemia Therapeutics Clinics , by Region USD Million (2023-2028)
  • Table 157. Acute Myeloid Leukemia Therapeutics Home Care , by Region USD Million (2023-2028)
  • Table 158. Acute Myeloid Leukemia Therapeutics: by Drug Type(USD Million)
  • Table 159. Acute Myeloid Leukemia Therapeutics Bosutinib , by Region USD Million (2023-2028)
  • Table 160. Acute Myeloid Leukemia Therapeutics Vidaza , by Region USD Million (2023-2028)
  • Table 161. Acute Myeloid Leukemia Therapeutics Omapro , by Region USD Million (2023-2028)
  • Table 162. Acute Myeloid Leukemia Therapeutics Quizartinib , by Region USD Million (2023-2028)
  • Table 163. Acute Myeloid Leukemia Therapeutics Dacogen , by Region USD Million (2023-2028)
  • Table 164. Acute Myeloid Leukemia Therapeutics Clolar , by Region USD Million (2023-2028)
  • Table 165. Acute Myeloid Leukemia Therapeutics Gleevac , by Region USD Million (2023-2028)
  • Table 166. Acute Myeloid Leukemia Therapeutics Sprycel , by Region USD Million (2023-2028)
  • Table 167. Acute Myeloid Leukemia Therapeutics Others , by Region USD Million (2023-2028)
  • Table 168. Acute Myeloid Leukemia Therapeutics: by Disease Type(USD Million)
  • Table 169. Acute Myeloid Leukemia Therapeutics Undifferentiated Acute Myeloblastic , by Region USD Million (2023-2028)
  • Table 170. Acute Myeloid Leukemia Therapeutics Acute Myeloblastic Leukemia with Minimal Maturation , by Region USD Million (2023-2028)
  • Table 171. Acute Myeloid Leukemia Therapeutics Acute Myeloblastic Leukemia with Maturation , by Region USD Million (2023-2028)
  • Table 172. Acute Myeloid Leukemia Therapeutics Acute Promyelocytic Leukemia (APL) , by Region USD Million (2023-2028)
  • Table 173. Acute Myeloid Leukemia Therapeutics Acute Myelomonocytic Leukemia , by Region USD Million (2023-2028)
  • Table 174. Acute Myeloid Leukemia Therapeutics Acute Myelomonocytic Leukemia with Eosinophilia , by Region USD Million (2023-2028)
  • Table 175. Acute Myeloid Leukemia Therapeutics Acute Monocytic Leukemia , by Region USD Million (2023-2028)
  • Table 176. Acute Myeloid Leukemia Therapeutics Acute Erythroid Leukemia , by Region USD Million (2023-2028)
  • Table 177. Acute Myeloid Leukemia Therapeutics Acute Megakaryoblastic Leukemia , by Region USD Million (2023-2028)
  • Table 178. South America Acute Myeloid Leukemia Therapeutics, by Country USD Million (2023-2028)
  • Table 179. South America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 180. South America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 181. South America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 182. South America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 183. Brazil Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 184. Brazil Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 185. Brazil Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 186. Brazil Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 187. Argentina Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 188. Argentina Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 189. Argentina Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 190. Argentina Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 191. Rest of South America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 192. Rest of South America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 193. Rest of South America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 194. Rest of South America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 195. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Country USD Million (2023-2028)
  • Table 196. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 197. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 198. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 199. Asia Pacific Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 200. China Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 201. China Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 202. China Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 203. China Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 204. Japan Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 205. Japan Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 206. Japan Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 207. Japan Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 208. India Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 209. India Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 210. India Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 211. India Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 212. South Korea Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 213. South Korea Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 214. South Korea Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 215. South Korea Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 216. Taiwan Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 217. Taiwan Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 218. Taiwan Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 219. Taiwan Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 220. Australia Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 221. Australia Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 222. Australia Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 223. Australia Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 224. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 225. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 226. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 227. Rest of Asia-Pacific Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 228. Europe Acute Myeloid Leukemia Therapeutics, by Country USD Million (2023-2028)
  • Table 229. Europe Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 230. Europe Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 231. Europe Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 232. Europe Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 233. Germany Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 234. Germany Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 235. Germany Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 236. Germany Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 237. France Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 238. France Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 239. France Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 240. France Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 241. Italy Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 242. Italy Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 243. Italy Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 244. Italy Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 245. United Kingdom Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 246. United Kingdom Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 247. United Kingdom Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 248. United Kingdom Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 249. Netherlands Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 250. Netherlands Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 251. Netherlands Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 252. Netherlands Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 253. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 254. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 255. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 256. Rest of Europe Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 257. MEA Acute Myeloid Leukemia Therapeutics, by Country USD Million (2023-2028)
  • Table 258. MEA Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 259. MEA Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 260. MEA Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 261. MEA Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 262. Middle East Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 263. Middle East Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 264. Middle East Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 265. Middle East Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 266. Africa Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 267. Africa Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 268. Africa Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 269. Africa Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 270. North America Acute Myeloid Leukemia Therapeutics, by Country USD Million (2023-2028)
  • Table 271. North America Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 272. North America Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 273. North America Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 274. North America Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 275. United States Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 276. United States Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 277. United States Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 278. United States Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 279. Canada Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 280. Canada Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 281. Canada Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 282. Canada Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 283. Mexico Acute Myeloid Leukemia Therapeutics, by Type USD Million (2023-2028)
  • Table 284. Mexico Acute Myeloid Leukemia Therapeutics, by Application USD Million (2023-2028)
  • Table 285. Mexico Acute Myeloid Leukemia Therapeutics, by Drug Type USD Million (2023-2028)
  • Table 286. Mexico Acute Myeloid Leukemia Therapeutics, by Disease Type USD Million (2023-2028)
  • Table 287. Acute Myeloid Leukemia Therapeutics: by Type(USD/Units)
  • Table 288. Research Programs/Design for This Report
  • Table 289. Key Data Information from Secondary Sources
  • Table 290. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acute Myeloid Leukemia Therapeutics: by Type USD Million (2017-2022)
  • Figure 5. Global Acute Myeloid Leukemia Therapeutics: by Application USD Million (2017-2022)
  • Figure 6. Global Acute Myeloid Leukemia Therapeutics: by Drug Type USD Million (2017-2022)
  • Figure 7. Global Acute Myeloid Leukemia Therapeutics: by Disease Type USD Million (2017-2022)
  • Figure 8. South America Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 9. Asia Pacific Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 10. Europe Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 11. MEA Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 12. North America Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 13. Global Acute Myeloid Leukemia Therapeutics: by Type USD/Units (2017-2022)
  • Figure 14. Global Acute Myeloid Leukemia Therapeutics share by Players 2022 (%)
  • Figure 15. Global Acute Myeloid Leukemia Therapeutics share by Players (Top 3) 2022(%)
  • Figure 16. Global Acute Myeloid Leukemia Therapeutics share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Ambit Biosciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Ambit Biosciences Corporation (United States) Revenue: by Geography 2022
  • Figure 20. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Celgene Corporation (United States) Revenue: by Geography 2022
  • Figure 22. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 24. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2022
  • Figure 28. Cephalon Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Cephalon Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Clavis Pharma ASA (United States) Revenue, Net Income and Gross profit
  • Figure 31. Clavis Pharma ASA (United States) Revenue: by Geography 2022
  • Figure 32. Eisai Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Eisai Co. Ltd. (Japan) Revenue: by Geography 2022
  • Figure 34. Genzyme Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 35. Genzyme Corporation (United States) Revenue: by Geography 2022
  • Figure 36. Sunesis Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Sunesis Pharmaceuticals Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Abbvie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Abbvie Inc. (United States) Revenue: by Geography 2022
  • Figure 40. Global Acute Myeloid Leukemia Therapeutics: by Type USD Million (2023-2028)
  • Figure 41. Global Acute Myeloid Leukemia Therapeutics: by Application USD Million (2023-2028)
  • Figure 42. Global Acute Myeloid Leukemia Therapeutics: by Drug Type USD Million (2023-2028)
  • Figure 43. Global Acute Myeloid Leukemia Therapeutics: by Disease Type USD Million (2023-2028)
  • Figure 44. South America Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 45. Asia Pacific Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 46. Europe Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 47. MEA Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 48. North America Acute Myeloid Leukemia Therapeutics Share (%), by Country
  • Figure 49. Global Acute Myeloid Leukemia Therapeutics: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Ambit Biosciences Corporation (United States)
  • Celgene Corporation (United States)
  • Bristol-Myers Squibb (United States)
  • Novartis International AG (Switzerland)
  • GlaxoSmithKline (United Kingdom)
  • Cephalon Inc. (United States)
  • Clavis Pharma ASA (United States)
  • Eisai Co. Ltd. (Japan)
  • Genzyme Corporation (United States)
  • Sunesis Pharmaceuticals Inc. (United States)
  • Abbvie Inc. (United States)
Additional players considered in the study are as follows:
Astellas Pharma Inc. (Japan) , CTI Biopharma Corp (United States)
Select User Access Type

Key Highlights of Report


Jul 2023 247 Pages 70 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acute Myeloid Leukemia Therapeutics Quantitative research analysis
Global Acute Myeloid Leukemia Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Acute Myeloid Leukemia Therapeutics Market are by type [Pipeline Drugs, Chemotherapy Drugs and Chemotherapy Regimens], by end use application [Hospitals, Clinics and Home Care].
The Acute Myeloid Leukemia Therapeutics Market is gaining popularity and expected to see strong valuation by 2028.
  • Rise in Awareness about the Leukemia Treatment
  • Increasing Number of Cancer Hospitals
  • Growing Population of Acute Myeloid Leukemia
  • A Rise in Changing Lifestyle and Family History

Know More About Global Acute Myeloid Leukemia Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Alopecia Comprehensive Study by Type (Oral treatment, Topical treatment, Other treatment), Application (Homecare Settings, Dermatology Clinics, Others (Salons)), Treatment (Vitamins and Supplements, ...
$ 3450
Endometriosis Treatment Comprehensive Study by Type (Gonadotropins releasing hormone agonists, Progestin, Non-steroidal anti-inflammatory drugs, Oral contraceptive pills), Application (Hospital pharm...
$ 3450
Pet Cancer Therapeutics Comprehensive Study by Type (Chemotherapy Drugs, Vaccines), Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer, Others), Treatment (Chemotherapy,...
$ 3450
Influenza Diagnostics Comprehensive Study by Type (Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Cu...
$ 3450
Prosthetic Heart Valves Comprehensive Study by Type (Transcatheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve), End User (Hospitals, Ambulatory Surgical Centers, Others) Players and Regi...
$ 3500
Cystoscope Comprehensive Study by Type (Rigid Cystoscope, Flexible Cystoscope), Application (Urology, Gynaecology), End User (Hospitals & Clinics, Ambulatory Surgical Centers) Players and Region - Gl...
$ 3500